The invention relates to radiolabelled girentuximab antibodies and humanised versions conjugated to a radionuclide Astatine211. The antibody conjugates are used in radiotherapy in treating urothelial cancer, including bladder cancer.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The invention relates to humanised antibodies for binding to the La/SSB antigen, antigen binding fragments derived therefrom, compositions comprising the antibodies or antigen binding fragments thereof, and uses thereof in methods of treatment.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
The present invention relates to methods for treating diseases and conditions characterised by aberrant cell growth, e.g., cancers, comprising administering a combination of a DNA repair inhibitor and a molecular targeted radioimmunotherapeutic agent.
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The disclosure provides a process of preparing an iron complexed conjugate between a desferrioxamine chelating ligand and a protein, the process being undertaken at a substantially neutral pH. A process of exposing an iron complexed conjugate to a free chelating ligand selected from desferrioxamine, a desferrioxamine analogue, and HBED, at a substantially neutral pH, in order to remove chelated iron from the iron complexed conjugate is also disclosed.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The disclosure provides methods of removing aggregate from a composition comprising a protein, an aggregate of the protein and a liquid carrier. The method involves subjecting the composition to one or more filtering steps comprising passing the composition through a cellulose acetate membrane to selectively adsorb at least some of the aggregate onto the membrane while substantially allowing the protein to pass through the membrane. Preferred protein compositions for aggregate removal comprise antibodies conjugated to chelating ligands.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
C07K 1/34 - ExtractionSeparationPurification by filtration, ultrafiltration or reverse osmosis
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
8.
ANTIBODIES AGAINST CAIX WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR
The invention relates to anti-CAIX antibodies comprising a heavy chain constant region comprising one or more amino acid substitutions compared to a wild-type IgG, wherein the one or more amino acid substitutions reduce the affinity of the antibody for the neonatal Fc receptor (FcRn), thereby reducing the serum half-life of the modified antibody compared to a wild-type antibody of class IgG. The one or more amino acid modification having the effect of reducing FcRn binding is selected from positions His310, His433, His435, His436, Ile253. Antibodies of the present invention are particularly suited for use in radioimmunotherapy.
The invention relates to reagents for in vivo imaging and detection of cancers that express platelet derived growth factor receptor alpha (PDGFR-alpha) using an olaratumab antibody, and methods of use thereof including methods for imaging cancers and methods for selecting patients for treatment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
G01N 33/534 - Production of labelled immunochemicals with radioactive label
10.
REAGENTS AND METHODS FOR IMAGING CANCERS EXPRESSING PDGFRALPHA
The invention relates to reagents for in vivo imaging and detection of cancers that express platelet derived growth factor receptor alpha (PDGFRalpha) using an olaratumab antibody, and methods of use thereof including methods for imaging cancers and methods for selecting patients for treatment.
The invention relates to compositions comprising an olaratumab antibody conjugated to a therapeutic radioisotope, for treatment of cancers that express platelet derived growth factor receptor alpha (PDGFR- alpha), and methods of use thereof.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The invention relates to compositions comprising an olaratumab antibody conjugated to a therapeutic radioisotope, for treatment of cancers that express platelet derived growth factor receptor alpha (PDGFR-alpha), and methods of use thereof.
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention relates to molecules comprising a tumour antigen binding protein and an extracellular domain (ECD) or ligand binding fragment of a transforming growth factor β receptor (TGFβR), and compositions and uses thereof.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to diagnosis and treatment of malignancies characterised by prostate-specific membrane antigen (PSMA) expression. The invention particularly relates to improved radiopharmaceuticals which selectively bind to PSMA and are suitable for planar imaging of PSMA expression in subjects to diagnose and/or monitor malignancies wherein PSMA is (over)expressed. Additionally, the invention relates to improved radiopharmaceuticals which selectively bind to PSMA and are suitable to act as radionuclide treatment agents. The radiopharmaceuticals rely on a pharmacophore capable of interacting with PSMA and N-terminal mercaptoacetyltripeptides capable of coordinating radioactive metals such as technetium and rhenium.
A method for in vivo imaging or detection of a cancer in a subject in need thereof, wherein the method comprises: - administering to the subject, an agent for binding to CAIX expressed by the cancer, wherein the agent comprises a detectable moiety for enabling in vivo detection of the agent in the subject, - detecting the agent in the subject, wherein the cancer is not renal cell carcinoma.
Processes for the synthesis of [8944 from [8944]4-salt are provided. The [8944 can be reacted with biomarker targeting agents to produce 89Zr labelled radiopharmaceuticals. The 89Zr labelled radiopharmaceuticals find use in, for example, non-invasive molecular imaging.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
18.
ANTIBODIES AGAINST CAIX WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR
The invention relates to anti-CAIX antibodies comprising a heavy chain constant region comprising one or more amino acid substitutions compared to a wild-type IgG, wherein the one or more amino acid substitutions reduce the affinity of the antibody for the neonatal Fc receptor (FcRn), thereby reducing the serum half-life of the modified antibody compared to a wild-type antibody of class IgG. The one or more amino acid modification having the effect of reducing FcRn binding is selected from positions His310, His433, His435, His436, Ile253. Antibodies of the present invention are particularly suited for use in radioimmunotherapy.
The invention relates to anti-PSMA antibodies comprising a heavy chain constant region comprising one or more amino acid substitutions compared to a wild-type IgG, wherein the one or more amino acid substitutions reduce the affinity of the antibody for the neonatal Fc receptor (FcRn), thereby reducing the serum half-life of the modified antibody compared to a wild-type antibody of class IgG. The one or more amino acid modification having the effect of reducing FcRn binding is selected from positions His310, His433, His435, His436, Ile253. Antibodies of the present invention are particularly suited for use in radioimmunotherapy.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
patents
